Chengchen Duan Email & Phone Number

Hong Kong Sar

• AI-Powered Drug Discovery: Collaborate with cross-functional teams to integrate AI models into drug discovery pipelines, optimising candidate selection and lead identification.• Data-Driven Solutions: Analyse and interpret large-scale biological and chemical datasets to support preclinical development and therapeutic innovation.• Scientific Collaboration: Work with internal R&D teams, external partners, and academic collaborators to align computational insights with experimental validation.• Application Development: Provide expertise in the application of AI tools for target discovery, small molecule design, and biomarker identification.• Reporting & Communication: Present findings to key stakeholders, ensuring clear and actionable communication of results and strategies.• Research Translation: Bridge the gap between computational models and experimental drug development processes, contributing to the successful acceleration of therapeutic pipelines.

Hong Kong Sar

• gRNA Editing & Oligonucleotide Delivery: Spearheaded innovative research projects focused on gRNA editing technologies and oligonucleotide delivery systems for RNA therapeutics.• Assay Development & Formulation Optimisation: Designed and optimized in vitro assays and delivery formulations, ensuring compliance with preclinical standards and achieving high yields.• IP Management: Conducted comprehensive intellectual property (IP) searches, Freedom to Operate (FTO) analyses, and drafted patents to protect proprietary RNA technologies.• Cross-functional Collaboration: Collaborated with internal R&D teams and external partners to integrate cutting-edge technologies into product pipelines.• Leadership & Mentorship: Mentored junior researchers and interns, fostering a culture of science and innovation.

Hong Kong Sar

Note: EDIRNA HK was established as a spin-off from Sirnaomics Ltd. to develop RNA editing and delivery technologies further.• Drug Discovery & Development: Contributed to RNA-based therapeutic programs, focusing on advancing oligonucleotide drug candidates for clinical development.• Strategic Reporting: Regularly reported project progress to the Director of the RNA Therapeutics & Technology Innovation Centre and other high-level management, ensuring alignment with organisational goals.• Collaboration: Played a key role in transitioning RNA therapeutic initiatives to EDIRNA HK during the spin-off process.

中国 广东省 深圳

1. Current work mainly focuses on two new lipid-based drug delivery system development projects with anti-cancer Pre-clinial Candidates (PCC) in-vitro and in-vivo DMPK studies and following development2. Mainly in charge of the in-vitro assay development based on cell models, organoids and in-situ organ culture model, in combination with analytical methods including UPLC and LC-MS/MS, for fast profiling and screening of candidate molecules

Brisbane, Australia

1. In-depth participation in the development of cutting-edge activatable fluorescence nanosensor projects, conducted imaging & bench-research work for the project. The data of the relevant project is independently analyzed and evaluated.2. Conducted literature & relevant data search for the nanosensor project.3. In-depth participation in one of the nanomaterials commercialization projects & investor negotiation.

Doctor Of Philosophy-Dphil, Nanotechnology/Biomedical Engineering

Thesis Title: Dual Functional Theranostic Nanoparticles for Rhabdomyosarcoma Treatment Conducted research on RNAi-based gene therapy.

Master Of Biotechnology Research Extensive, Biotechnology, 6.625/7

1. Graduated with Distinction (GPA 6.625/7), awarded the Dean's Commendation for Academic Excellence both in 2016-2017, 2017-2018. 2..

Bachelor Of Science - Bs, Biotechnology

Top 15%, were awarded several competitive scholarships during the study.